AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
May 19, 2021
29864_dirs_2021-05-19_179ad52a-81eb-427b-a345-9e786ebc6d4e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-05-17
Reporting Person: Arbuckle Stuart A (EVP, Chief Comm & Ops Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-17 | Common Stock | S | 7 | $215.33 | Disposed | 41205 | Direct |
| 2021-05-17 | Common Stock | S | 86 | $216.36 | Disposed | 41119 | Direct |
| 2021-05-17 | Common Stock | S | 16 | $217.15 | Disposed | 41103 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 140 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $215.33 (range $214.82 to $215.80).
F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $216.36 (range $215.82 to $216.76).
F5: Open market sales reported on this line occurred at a weighted average price of $217.15 (range $216.83 to $217.32).